Beddow Capital Management Inc. grew its holdings in Organon & Co. (NYSE:OGN - Free Report) by 230.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 174,970 shares of the company's stock after purchasing an additional 122,091 shares during the period. Organon & Co. makes up 1.2% of Beddow Capital Management Inc.'s investment portfolio, making the stock its 28th largest position. Beddow Capital Management Inc. owned 0.07% of Organon & Co. worth $2,523,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of OGN. Wellington Shields Capital Management LLC acquired a new position in Organon & Co. during the 4th quarter worth about $27,000. Harvest Fund Management Co. Ltd lifted its stake in Organon & Co. by 495.5% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company's stock worth $28,000 after acquiring an additional 1,333 shares in the last quarter. Headlands Technologies LLC acquired a new position in Organon & Co. during the 3rd quarter worth about $35,000. EverSource Wealth Advisors LLC lifted its stake in Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company's stock worth $39,000 after acquiring an additional 1,110 shares in the last quarter. Finally, Clear Street Markets LLC lifted its stake in Organon & Co. by 588.9% during the 3rd quarter. Clear Street Markets LLC now owns 2,294 shares of the company's stock worth $40,000 after acquiring an additional 1,961 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group increased their price target on Organon & Co. from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Tuesday, February 20th.
View Our Latest Stock Analysis on Organon & Co.
Organon & Co. Stock Performance
OGN stock traded up $0.30 during mid-day trading on Monday, reaching $18.16. The company had a trading volume of 1,285,675 shares, compared to its average volume of 2,802,377. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of 4.54, a price-to-earnings-growth ratio of 0.85 and a beta of 0.83. The firm has a fifty day simple moving average of $17.78 and a 200 day simple moving average of $15.57.
Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. As a group, analysts predict that Organon & Co. will post 4.08 earnings per share for the current year.
Organon & Co. Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were issued a $0.28 dividend. The ex-dividend date was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.17%. Organon & Co.'s payout ratio is currently 28.00%.
Insider Activity
In other news, insider Kirke Weaver purchased 2,720 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares of the company's stock, valued at approximately $278,723.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.17% of the company's stock.
About Organon & Co.
(
Free Report)
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Further Reading
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
